中国工业和信息化部等十部门于2026年9月18日发布《医药工业发展"十五五"规划》，明确提出到2030年生物医药研发应用稳居世界前列的目标1。规划部署八个方面共25项重点任务，并设置了一系列具体指标1。
在发展规模方面，规划要求医药工业企业营业收入超过3.5万亿元1，创新药产业规模年均增速达20%以上1，年营业收入超100亿元的企业达到50家1，千亿级医药产业园区达到20个1。研发创新能力方面，医药工业上市企业平均研发投入强度要达到年均10%以上1，创新医疗器械上市数量达200个以上1，首创新药占全球比例达25%以上1。此外，规划还明确了全球年销售额超10亿美元的品种要达到5个以上的目标1。
China's Ministry of Industry and Information Technology and nine other departments jointly released the "Pharmaceutical Industry Development Fifteenth Five-Year Plan" on September 18, 2026, establishing a comprehensive framework to position the nation's biopharmaceutical sector among global leaders by 2030 1. The plan outlines eight priority areas encompassing 25 key tasks designed to accelerate innovation and industrial growth across the pharmaceutical and medical device sectors 1.
The policy sets specific quantitative targets reflecting the scope of ambition guiding the sector's development. By 2030, pharmaceutical industry enterprises are expected to achieve combined operating revenue exceeding 3.5 trillion yuan, with the innovative drug segment growing at an average annual rate of 20 percent or higher 1. The plan also calls for at least five innovative drug products to achieve annual global sales exceeding one billion dollars each, while first-in-class new drugs developed domestically should account for 25 percent or more of global introductions 1.
Additional benchmarks demonstrate the plan's focus on technological advancement and industry consolidation. Listed pharmaceutical companies are expected to maintain average annual research and development investment intensity of 10 percent or above, while the number of innovative medical devices cleared for market is targeted at 200 or more 1. The plan envisions the emergence of at least 50 enterprises with annual operating revenues exceeding one billion yuan and the development of 20 industrial parks each generating one billion yuan in annual revenue 1.
评论
还没有评论，欢迎留下第一条。